Tramadol: does it have a role in cancer pain management?

Title

Tramadol: does it have a role in cancer pain management?

Creator

Prommer EE

Publisher

Journal Of Opioid Management

Date

2005

Subject

Humans; Analgesics; Methadone; Pain/drug therapy/etiology; Neoplasms/complications; Opioid/adverse effects/chemistry/pharmacokinetics/therapeutic use; Tramadol/adverse effects/chemistry/pharmacokinetics/therapeutic use

Description

Tramadol (Ultram, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) is considered a Step 2 analgesic under the World Health Organization's guidelines for the treatment of patients with cancer pain. It is a centrally acting analgesic that has affinity for opioid receptors and influences the action of norepinephrine and serotonin at the synapse. This dual mechanism of analgesia makes it unique among Step 2 agents. It is metabolized by CYP2D6, which increases the potentialfor drug interactions. Unlike other opioids, it does not cause respiratory depression. Tramadol has been studied in cancer pain and neuropathic pain. It compares well with low-dose morphine as an analgesic. The purpose of this review is to critically examine the pharmacodynamics, pharmacology, drug interactions, and adverse effects of the drug, and, based on the data presented, discuss the drug's role in cancer care.
2005

Rights

Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).

Type

Journal Article

Citation List Month

Backlog

Pages

131-138

Issue

3

Volume

1

Citation

Prommer EE, “Tramadol: does it have a role in cancer pain management?,” Pediatric Palliative Care Library, accessed May 16, 2022, https://pedpalascnetlibrary.omeka.net/items/show/13255.

Social Bookmarking